Creating transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early development capabilities
Focus on identifying GPCR targets across multiple disease areas
PR Newswire
TOKYO and CAMBRIDGE, England, July 6, 2021